
    
      Six patients enrolled at each dose level of 0.3, 1.0, 3.0 and 10mg/kg; the remaining 10 to 15
      patients may subsequently be enrolled at a dose at or below the maximum tolerated dose (MTD)
      during the dose-escalation portion of the study. Patients who respond may receive additional
      doses of drug.
    
  